NCT02178800: A trial that was reported late by National Institute of Allergy and Infectious Diseases (NIAID)
This trial has reported, although it was 25 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT02178800 |
|---|---|
| Title | A Phase IIa Study to Evaluate the Safety, Tolerability and Pharmacokinetics of the Investigational Injectable HIV Integrase Inhibitor, GSK1265744, in HIV-uninfected Men and Women |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | Feb. 28, 2015 |
| Completion date | April 5, 2017 |
| Required reporting date | April 5, 2018, midnight |
| Actual reporting date | April 30, 2018 |
| Date last checked at ClinicalTrials.gov | March 28, 2025 |
| Days late | 25 |